Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

aive and treatment experienced HCV patients. In addition, the company was issued a US patent covering R7128.

Results from the 28 day study were presented at the recent American Association for the Study of Liver Diseases (AASLD) that demonstrated that R7128 combined with the standard of care (pegylated interferon and ribavirin) provided significant short-term antiviral activity with safety and tolerability comparable to the standard of care alone. Results from the 500mg BID, 1000mg BID, 1500mg BID dose cohorts in 81 treatment-naive patients chronically infected with HCV genotype 1 indicated rapid virological response (RVR) rates of 30% (6 of 20), 88% (22 of 25) and 85% (17 of 20), respectively compared to 19% (3 of 16) in the control group. Further results in genotype 2 and 3, non responder patients treated with 1500mg BID generated RVR rate of 90% (18 of 20) versus 60% (3 of 5) in the control group. Across all studies, safety and tolerability of R7128 combined with peginterferon and ribavirin was similar to the standard of care alone.

Based on these results and other data, Pharmasset's partner, Roche, plans to move R7128 into a phase 2b trial in HCV-1 infected patients in the first calendar quarter of 2009. Pharmasset has submitted the necessary briefing documents to the FDA and both Roche and Pharmasset plan to meet with the agency in early January to review the preclinical and clinical data and to discuss the phase 2b design and future studies.

In addition to planning for phase 2b, Roche initiated the INFORM-1 trial, a potentially ground-breaking study to investigate the activity of a combination of two oral antiviral molecules in the absence of interferon. The study began in November 2008, and will investigate the combination of Pharmasset's R7128 with InterMune's R7227, a protease inhibitor. The first cohort of patients has been enrolled and preliminary results from this study are expected in fi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... in the U.S. and XIAPEX ® in the ... will present a corporate overview at the 21 st ... The presentation will take place on Friday, September 26, ... in New York, NY . A live ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... General Dynamics Information Technology, a business unit of General ... a contract to support the U.S. Army Medical Department,s ... facilities and transition to newly constructed facilities. The indefinite ... by the U.S. Army Corps of Engineers, has a ...
... Oct. 12 Misonix, Inc. (Nasdaq: MSON ... medical device technology, which worldwide is used for acute ... its non-exclusive distribution arrangement in the United States with ... As a result, Misonix will assume exclusive ...
Cached Medicine Technology:General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities 2General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities 3Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S. 2
(Date:9/19/2014)... published today in the online journal PLoS Outbreaks ... West Africa by the end of the month if ... State University and Harvard University researchers also discovered through ... significantly increased in August in Liberia and Guinea, around ... place, indicating that the mass quarantine efforts may have ...
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... led by Medical College of Wisconsin (MCW) scientists has identified ... in rats, mice and in humans. The findings are published ... , Leah Solberg Woods, Ph.D., associate professor of pediatrics ... Wisconsin Research Institute, led the study and is the corresponding ... identified a gene called Tpcn2 in which a variant was ...
(Date:9/19/2014)... 19, 2014 Capital Region Periodontics ... is excited to announce the latest addition to ... gingivitis and those needing dental implants. Often referred ... treatment removes the fear factor normally associated with ... discomfort and bleeding make, this procedure a very ...
(Date:9/19/2014)... researchers say a simple test that combines thinking ... for developing Alzheimer,s disease in a person, even ... dementia., Faculty of Health Professor Lauren Sergio and ... asked the participants to complete four increasingly demanding ... computers. The test aimed at detecting the tendency ...
Breaking Medicine News(10 mins):Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2
... survey conducted in US in 2002 and observed that half of ... have had previous ones earlier. ,Women who had come ... 30, were from a large family and with low income. Most ... conceived in spite of it. ,Abortions are not uncommon ...
... South Korea has caused Japan to temporarily suspend the ... around 6000 chickens have died as a result of ... outbreak have been sought from South Korea. "As a ... Korean poultry", Chief Cabinet Secretary Yasuhisa Shiozaki of Japan ...
... of botulism following cosmetic injections to the face indicates ... that resulted in toxin levels up to 40 times ... ,Botulism is a rare paralytic illness caused by ... toxin-producing strains of Clostridium baratii and Clostridium butyricum. Botulism, ...
... a cheap and simple way of cutting heart disease ... to a study by heart experts, folic acid could ... blood considered to be a cause of cardiovascular disease, ... from the London School of Medicine and Barts Hospital, ...
... Two recent articles in Science by researchers at Yale School ... the risk of developing //the aggressive 'wet' form of age-related ... people over age 50. ,AMD causes light-sensitive cells ... of central vision. Of the two forms of AMD, the ...
... for Ageing, Senator Santo Santoro, to discuss the issue of ... AMA's Federal Budget Submission 2007-08. ,The current ... difficult for GPs to provide ongoing care to residents of ... Haikerwal, said today the number of general practitioners able to ...
Cached Medicine News:Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 2Health News:Highly-Concentrated Botulinum Preparation Can Result in Severe Illness 3Health News:Gene Linked With Aggressive 'Wet' Form Of AMD 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: